Oppenheimer Cuts Prestige Consumer Healthcare (NYSE:PBH) Price Target to $65.00

Prestige Consumer Healthcare (NYSE:PBH) had its target price trimmed by Oppenheimer from $77.00 to $65.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other research analysts have also recently issued reports on the company. Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.75.

Prestige Consumer Healthcare Trading Down 3.8%

PBH opened at $52.53 on Thursday. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of 13.90, a P/E/G ratio of 1.58 and a beta of 0.40. The stock’s 50 day moving average price is $60.23 and its 200-day moving average price is $61.92. Prestige Consumer Healthcare has a one year low of $51.24 and a one year high of $89.37. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company’s quarterly revenue was down 2.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.22 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.54 EPS for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 2,553 shares of company stock worth $151,444 in the last ninety days. 1.40% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its holdings in Prestige Consumer Healthcare by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock worth $158,414,000 after buying an additional 91,710 shares during the period. State Street Corp lifted its holdings in Prestige Consumer Healthcare by 1.4% during the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after buying an additional 27,721 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Prestige Consumer Healthcare by 1.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after buying an additional 21,085 shares during the period. Morgan Stanley lifted its holdings in Prestige Consumer Healthcare by 6.3% during the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after buying an additional 71,078 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 5.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after purchasing an additional 35,126 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Trending Headlines about Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Oppenheimer kept an Outperform rating on PBH, even after trimming its price target to $65 from $77, suggesting the stock still has upside from recent levels. Article source
• Neutral Sentiment: Analysts continue to see a reasonable earnings trajectory for PBH, with consensus full-year EPS at $4.54 and Zacks projecting $4.76 for FY2027 and $5.05 for FY2028.
• Neutral Sentiment: A broader analyst note highlighted upcoming Q4 earnings expectations, but no new company guidance or major business update was reported in the article. Article source
• Negative Sentiment: Zacks Research cut EPS estimates for PBH, including lowering Q2 2028 estimates to $1.24 from $1.30 and trimming FY2027/FY2028 forecasts slightly, which can signal softer long-term expectations.
• Negative Sentiment: Insider selling added to the cautious tone: VP Jeffrey Zerillo sold shares in two May 5 transactions, including 1,207 shares and 346 shares, both disclosed under a pre-arranged trading plan.
• Negative Sentiment: PBH’s latest earnings report missed expectations, with EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated, while revenue fell 2.4% year over year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).